Patents by Inventor Jens WILLWACHER

Jens WILLWACHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101561
    Abstract: This invention relates to tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 14, 2020
    Publication date: March 28, 2024
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Uta Friederike LESSEL, Jens WILLWACHER
  • Publication number: 20240059675
    Abstract: The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: July 31, 2023
    Publication date: February 22, 2024
    Inventors: Jens WILLWACHER, Florian Paul Christian BINDER, Georg DAHMANN, James Young Soo YANG HAMILTON, Sandra Ruth HANDSCHUH, Sophia Astrid REINDL
  • Patent number: 11891403
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: February 6, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Patent number: 11884652
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: January 30, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • Patent number: 11858921
    Abstract: The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 2, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • Publication number: 20230257395
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 19, 2023
    Publication date: August 17, 2023
    Inventors: Florian Paul Christian BINDER, Thomas Martin FLECK, Jens WILLWACHER
  • Patent number: 11661430
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Thomas Martin Fleck, Jens Willwacher
  • Patent number: 11661427
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Publication number: 20230065629
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
  • Patent number: 11578080
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Uta Friederike Lessel, Jens Willwacher
  • Publication number: 20220340590
    Abstract: The present disclosure provides certain 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Florian Paul Christian BINDER, Jens WILLWACHER, Martin Thomas FLECK
  • Publication number: 20220340552
    Abstract: The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Florian Paul Christian BINDER, Martin Thomas FLECK, Jens WILLWACHER
  • Publication number: 20220112202
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Jens WILLWACHER
  • Publication number: 20220112210
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Florian Paul Christian BINDER, Thomas Martin FLECK, Jens WILLWACHER
  • Publication number: 20220002270
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 6, 2022
    Inventors: Florian Paul Christian BINDER, Martin Thomas FLECK, Jens WILLWACHER
  • Publication number: 20210403482
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: June 24, 2021
    Publication date: December 30, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Jens WILLWACHER
  • Patent number: 11208400
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 28, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
  • Publication number: 20210395267
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Uta Friederike LESSEL, Jens WILLWACHER
  • Patent number: 11136336
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Jens Willwacher
  • Publication number: 20210107918
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Jens WILLWACHER